ArticleAmerican journal of translational research2023
Effect of butylphthalide injection combined with gastrodin to improve sTRAIL and inflammatory factors in elderly patients with cerebral infarction.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- Effectiveness and Safety of Butyphthalide Injection in Treatment of Aphasia after Cerebral Infarction: A Meta-analysis.Combinatorial chemistry & high throughput screening · 2026Pooled it
- The protective effects of gastrodin on neurological disorders: an update and future perspectives.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis research was designed to probe into the effect of butylphthalide injection combined with gastrodin on sTRAIL and inflammatory factors in elderly patients with cerebral infarction (CI).
methodsElderly CI patients admitted to the Strategic Support Force Characteristic Medical Center from June 2019 to September 2021 were collected for this retrospective analysis, and then divided into Group A and B. Patients in group A were given gastrodin injection by intravenous drip, and those in group B were treated with butylphthalide injection additionally. The general data, efficacy and adverse reactions of patients were observed and compared. The neurological impairment (NIHSS) score before and after treatment was analyzed. The activities of daily living and Barthel index (BI) after treatment were tested. The levels of sTRAIL and inflammatory factors were assessed before and after treatment. Their quality of life (SF-36 score) was observed before and after treatment. Logistic regression was used to analyze the risk factors affecting patient prognosis.
resultsThere was no difference in general data between the two groups (P>0.05). Compared with group A, group B showed higher total effective rate (P<0.05), lower total incidence of adverse reactions (P<0.05), and lower NIHSS scores after treatment (P<0.05). Besides, after treatment, the levels of sTRAIL and inflammatory factors were lower (P<0.05), BI was higher (P<0.05), and the quality of life was better (P<0.05) in group B than in group A. Age and NIHSS score were risk factors for poor prognosis (P<0.05).
conclusionButylphthalide injection combined with gastrodin is better than gastrodin alone in the treatment of senile CI. This combination can improve the neurological function and activities of daily living and reduce the levels of serum sTRAIL and inflammatory factors in patients.
Indexed as
Identifiers
37193165PMC10182533W4376872926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.